Table 2.
The multiple comparison of between-group variance of survival analysis.
| Sintilimab vs duplex | Sintilimab vs triple | Duplex vs triple | ||||
|---|---|---|---|---|---|---|
| χ2 | p value* | χ2 | p value* | χ2 | p value* | |
| OS | 7.80 | 0.005 | 22.29 | < 0.001 | 4.21 | 0.040 |
| PFS | 6.86 | 0.009 | 11.96 | 0.001 | 0.57 | 0.450 |
| DOR | 0.04 | 0.850 | 3.90 | 0.048 | 2.67 | 0.103 |
| DDC | 0.13 | 0.722 | 4.00 | 0.045 | 5.14 | 0.023 |
| ORR | 1.09 | 0.297 | 1.71 | 0.191 | 0.04 | 0.836 |
| DCR | 8.01 | 0.005 | 13.23 | < 0.001 | 0.30 | 0.587 |
| CBR | 2.72 | 0.099 | 9.42 | 0.002 | 2.12 | 0.145 |
OS overall survival, PFS progression free survival, DOR duration of object response, DDC duration of disease control, ORR object response rate, DCR disease control rate, CBR clinical benefit rate.
*Compared with each group (Kaplan–Meier Analysis or Pearson’s chi-square test), p value < 0.05 was considered statistically significant.